Secondly, while we demonstrated that Lyc.HCL inhibits cancer cell growth, metastasis, and invasiveness by targeting TRIM22 and modulating the JAK2/STAT3 and ERK pathways in vitro and in vivo, our in vivo experiments were limited to a subcutaneous xenograft model. This evidence concerns the gene JAK2 and cancer.